Stoke Therapeutics, Inc. – NASDAQ:STOK
Founder-led company
Stoke Therapeutics stock price today
$18.3
+7.24
+65.46%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 4 hours
Stoke Therapeutics stock price monthly change
-22.39%
month
Stoke Therapeutics stock price quarterly change
-22.39%
quarter
Stoke Therapeutics stock price yearly change
+106.73%
year
Stoke Therapeutics key metrics
Market Cap | 609.65M |
Enterprise value | N/A |
P/E | -3.21 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 25.36 |
Price/Book | 1.70 |
PEG ratio | 0.28 |
EPS | -2.41 |
Revenue | 7.84M |
EBITDA | -116.12M |
Income | -108.52M |
Revenue Q/Q | -18.16% |
Revenue Y/Y | -46.10% |
Profit margin | -814.73% |
Oper. margin | -841.24% |
Gross margin | 26.05% |
EBIT margin | -841.24% |
EBITDA margin | -1480.25% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeStoke Therapeutics stock price history
Stoke Therapeutics stock forecast
Stoke Therapeutics financial statements
Average Price Target
$26.5
Potential upside: 44.80%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | -2.48M | -30.65M | 1235.55% |
|---|---|---|---|
| Sep 2023 | 3.30M | -24.54M | -741.9% |
| Dec 2023 | 2.80M | -26.95M | -962.1% |
| Mar 2024 | 4.21M | -26.37M | -625.57% |
| Jun 2023 | 256919000 | 66.72M | 25.97% |
|---|---|---|---|
| Sep 2023 | 239889000 | 66.89M | 27.88% |
| Dec 2023 | 228342000 | 68.77M | 30.12% |
| Mar 2024 | 205182000 | 64.84M | 31.6% |
| Jun 2023 | -21.8M | 23.47M | 48K |
|---|---|---|---|
| Sep 2023 | -17.26M | 14.61M | 562K |
| Dec 2023 | -20.64M | 14.77M | 7.34M |
| Mar 2024 | -24.56M | 9.98M | 1.71M |
Stoke Therapeutics alternative data
| Aug 2023 | 117 |
|---|---|
| Sep 2023 | 117 |
| Oct 2023 | 117 |
| Nov 2023 | 117 |
| Dec 2023 | 117 |
| Jan 2024 | 117 |
| Feb 2024 | 117 |
| Mar 2024 | 110 |
| Apr 2024 | 110 |
| May 2024 | 110 |
| Jun 2024 | 110 |
| Jul 2024 | 110 |
Stoke Therapeutics other data
37.26%
-62.74%
of STOK is owned by hedge funds
57
-49
14.49M
-25.79M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 10000 |
| Feb 2024 | 0 | 10000 |
| Mar 2024 | 0 | 40973 |
| Apr 2024 | 0 | 3670755 |
| May 2024 | 0 | 110949 |
| Jun 2024 | 0 | 10000 |
| Jul 2024 | 0 | 12500 |
| Aug 2024 | 0 | 10000 |
| Sep 2024 | 0 | 1947500 |
| Oct 2024 | 0 | 10000 |
| Nov 2024 | 0 | 10000 |
| Dec 2024 | 0 | 2062849 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | SKORPIOS TRUST 10 percent owner | Common Stock | 2,000,000 | $11.5 | $23,000,000 | ||
Sale | TICHO BARRY officer: CHIEF MEDICAL OFFICER | Common Stock | 2,586 | $12.99 | $33,595 | ||
Sale | ALLAN JONATHAN officer: GENERAL COUNSEL & CORP.. | Common Stock | 12,114 | $13.69 | $165,816 | ||
Sale | ALLAN JONATHAN officer: GENERAL COUNSEL & CORP.. | Common Stock | 1,552 | $12.99 | $20,164 | ||
Sale | KAYE EDWARD M. MD director, officer.. | Common Stock | 6,786 | $12.99 | $88,157 | ||
Sale | KAYE EDWARD M. MD director, officer.. | Common Stock | 6,786 | $12.99 | $88,157 | ||
Sale | TICHO BARRY officer: CHIEF MEDICAL OFFICER | Common Stock | 13,945 | $12.78 | $178,189 | ||
Sale | ALLAN JONATHAN officer: GENERAL COUNSEL & CORP.. | Common Stock | 9,696 | $12.78 | $123,895 | ||
Sale | KAYE EDWARD M. MD director, officer.. | Common Stock | 6,170 | $12.78 | $78,840 | ||
Sale | KAYE EDWARD M. MD director, officer.. | Common Stock | 6,170 | $12.78 | $78,840 |
| Patent |
|---|
Application Filling date: 3 Nov 2021 Issue date: 26 May 2022 |
Application Filling date: 26 Aug 2021 Issue date: 26 May 2022 |
Application Filling date: 3 Nov 2021 Issue date: 28 Apr 2022 |
Application Filling date: 19 Jul 2021 Issue date: 21 Apr 2022 |
Application Filling date: 23 Jun 2021 Issue date: 24 Mar 2022 |
Application Filling date: 3 May 2019 Issue date: 2 Dec 2021 |
Application Filling date: 18 Dec 2020 Issue date: 7 Oct 2021 |
Application Filling date: 23 Oct 2018 Issue date: 2 Sep 2021 |
Grant Utility: Antisense oligomers and uses thereof Filling date: 13 Jun 2018 Issue date: 24 Aug 2021 |
Grant Utility: Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome Filling date: 14 Dec 2016 Issue date: 10 Aug 2021 |
| Insider | Compensation |
|---|---|
| Dr. Edward M. Kaye (1949) Chief Executive Officer & Director | $958,050 |
Dr. Barry S. Ticho FACC, M.D., Ph.D. (1960) Chief Medical Officer | $662,500 |
Mr. Stephen J. Tulipano CPA, CPA, MBA (1959) Chief Financial Officer | $611,450 |
| Dr. Adrian R. Krainer Ph.D. (1959) Co-Founder, Independent Director & Member of Scientific Advisory Board | $39,000 |
NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration
Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Stoke Therapeutics Is Unable To Derisk Its Platform
Stoke Therapeutics Looks Unfairly Valued
Buy Stoke Therapeutics At A Deep Discount Following Early Data In Dravet Syndrome
Longboard Pharmaceuticals: Arena Team's Next Act Is Flying Under The Radar
-
What's the price of Stoke Therapeutics stock today?
One share of Stoke Therapeutics stock can currently be purchased for approximately $18.3.
-
When is Stoke Therapeutics's next earnings date?
Unfortunately, Stoke Therapeutics's (STOK) next earnings date is currently unknown.
-
Does Stoke Therapeutics pay dividends?
No, Stoke Therapeutics does not pay dividends.
-
How much money does Stoke Therapeutics make?
Stoke Therapeutics has a market capitalization of 609.65M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 29.22% to 8.78M US dollars.
-
What is Stoke Therapeutics's stock symbol?
Stoke Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "STOK".
-
What is Stoke Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Stoke Therapeutics?
Shares of Stoke Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Stoke Therapeutics's key executives?
Stoke Therapeutics's management team includes the following people:
- Dr. Edward M. Kaye Chief Executive Officer & Director(age: 76, pay: $958,050)
- Dr. Barry S. Ticho FACC, M.D., Ph.D. Chief Medical Officer(age: 65, pay: $662,500)
- Mr. Stephen J. Tulipano CPA, CPA, MBA Chief Financial Officer(age: 66, pay: $611,450)
- Dr. Adrian R. Krainer Ph.D. Co-Founder, Independent Director & Member of Scientific Advisory Board(age: 66, pay: $39,000)
-
Is Stoke Therapeutics founder-led company?
Yes, Stoke Therapeutics is a company led by its founder Dr. Adrian R. Krainer Ph.D..
-
How many employees does Stoke Therapeutics have?
As Jul 2024, Stoke Therapeutics employs 110 workers.
-
When Stoke Therapeutics went public?
Stoke Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 19 Jun 2019.
-
What is Stoke Therapeutics's official website?
The official website for Stoke Therapeutics is stoketherapeutics.com.
-
Where are Stoke Therapeutics's headquarters?
Stoke Therapeutics is headquartered at 45 Wiggins Avenue, Bedford, MA.
-
How can i contact Stoke Therapeutics?
Stoke Therapeutics's mailing address is 45 Wiggins Avenue, Bedford, MA and company can be reached via phone at +7 814308200.
-
What is Stoke Therapeutics stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Stoke Therapeutics in the last 12 months, the avarage price target is $26.5. The average price target represents a 44.80% change from the last price of $18.3.
Stoke Therapeutics company profile:
Stoke Therapeutics, Inc.
stoketherapeutics.comExchange:
NASDAQ
Full time employees:
110
Industry:
Biotechnology
Sector:
Healthcare
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
45 Wiggins Avenue
Bedford, MA 01730
Bedford, MA 01730
CIK: 0001623526
ISIN: US86150R1077
CUSIP: 86150R107
